C-reactive protein and response to lurasidone in patients with bipolar depression

Brain, Behavior, and Immunity

Volumn 73, Issue , 2018, Pages 717-724

  Raison, Charles L ^a,b   Pikalov, Andrei ^c   Siu, Cynthia ^d   Tsai, Joyce ^c   Koblan, Kenneth ^c   Loebel, Antony ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^d Department of Data Science   (Hong Kong)

Author keywords

Atypical antipsychotics; Bipolar depression; C reactive protein; Inflammation; Lurasidone; Predictive biomarkers

Indexed keywords

C REACTIVE PROTEIN; LURASIDONE; PLACEBO; ANTIDEPRESSANT AGENT; PHARMACOLOGICAL BIOMARKER; TRANQUILIZER;

ADULT; AGED; ARTICLE; BIPOLAR DEPRESSION; BODY MASS; BODY WEIGHT CHANGE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; BIPOLAR DISORDER; BLOOD; MAJOR DEPRESSION; METABOLISM; MIDDLE AGED; OUTPATIENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BIPOLAR DISORDER; C-REACTIVE PROTEIN; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 85051369353     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2018.08.009     Document Type: Article

References (50)

1. Abler, B., Grön, G., Hartmann, A., Metzger, C., Walter, M., Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs. J. Neurosci. 32 (2012), 1329–1335, 10.1523/JNEUROSCI.5826-11.2012.
2. Calabrese, J.R., Hirschfeld, R.M.A., Frye, M.A., Reed, M.L., Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J. Clin. Psychiatry 65 (2004), 1499–1504.
3. Capuron, L., Pagnoni, G., Drake, D.F., Woolwine, B.J., Spivey, J.R., Crowe, R.J., et al. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch. Gen. Psychiatry 69 (2012), 1044–1053, 10.1001/archgenpsychiatry.2011.2094.
4. Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K.J., et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline “predictors” and longitudinal “targets”. Neuropsychopharmacology 38 (2013), 377–385, 10.1038/npp.2012.191.
5. Corona, A.W., Norden, D.M., Skendelas, J.P., Huang, Y., O'Connor, J.C., Lawson, M., et al. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav. Immun. 31 (2013), 134–142, 10.1016/j.bbi.2012.08.008.
6. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56, 10.1038/nrn2297.
7. Dargél, A.A., Godin, O., Kapczinski, F., Kupfer, D.J., Leboyer, M., C-reactive protein alterations in bipolar disorder: a meta-analysis. J. Clin. Psychiatry 76 (2015), 142–150, 10.4088/JCP.14r09007.
8. Eisenberger, N.I., Inagaki, T.K., Mashal, N.M., Irwin, M.R., Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav. Immun. 24 (2010), 558–563.
9. Fagiolini, A., Forgione, R., Maccari, M., Cuomo, A., Morana, B., Dell'Osso, M.C., et al. Prevalence, chronicity, burden and borders of bipolar disorder. J. Affect. Disord. 148 (2013), 161–169, 10.1016/j.jad.2013.02.001.
10. Felger, J.C., Li, Z., Haroon, E., Woolwine, B.J., Jung, M.Y., Hu, X., et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry 21 (2016), 1358–1365, 10.1038/mp.2015.168.
11. Fernandes, B.S., Steiner, J., Bernstein, H.G., Dodd, S., Pasco, J.A., Dean, O.M., et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol. Psychiatry 21 (2016), 554–564, 10.1038/mp.2015.87.
12. Fitzmaurice, G.M., Laird, N.M., Ware, J.H., Applied Longitudinal Analysis. 2004, John Wiley and Sons Inc, New Jersey.
13. Gao, K., Fang, F., Wang, Z., Calabrese, J.R., Subjective versus objective weight gain during acute treatment with second-generation antipsychotics in schizophrenia and bipolar disorder. J. Clin. Psychopharmacol. 36 (2016), 637–642, 10.1097/JCP.0000000000000596.
14. Guilloux, J.-P., Bassi, S., Ding, Y., Walsh, C., Turecki, G., Tseng, G., et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology 40 (2015), 701–710, 10.1038/npp.2014.226.
15. Haroon, E., Miller, A.H., Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications. Current topics in behavioral neurosciences 31 (2017), 173–198, 10.1007/7854_2016_40.
16. Hope, S., Dieset, I., Agartz, I., Steen, N.E., Ueland, T., Melle, I., et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J. Psychiatry Res. 45 (2011), 1608–1616, 10.1016/j.jpsychires.2011.08.003.
17. Huang, M., Panos, J.J., Kwon, S., Oyamada, Y., Rajagopal, L., Meltzer, H.Y., Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J. Neurochem. 128 (2014), 938–949, 10.1111/jnc.12512.
18. Hung, Y.Y., Lin, C.C., Kang, H.Y., Huang, T.L., TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder. Brain Behav. Immun. 59 (2017), 265–272, 10.1016/j.bbi.2016.09.014.
19. Jamison, K.R., Suicide and bipolar disorder. J. Clin. Psychiatry 61:Suppl. 9 (2000), 47–51.
20. Jha, M.K., Minhajuddin, A., Gadad, B.S., Greer, T., Grannemann, B., Soyombo, A., et al. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 78 (2017), 105–113, 10.1016/j.psyneuen.2017.01.023.
21. Judd, L.L., Akiskal, H.S., Schettler, P.J., Endicott, J., Maser, J., Solomon, D.A., et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59 (2002), 530–537.
22. Kitamura, Y., Yagi, T., Kitagawa, K., Shinomiya, K., Kawasaki, H., Asanuma, M., et al. Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. Naunyn Schmiedebergs Arch. Pharmacol. 382 (2010), 151–158, 10.1007/s00210-010-0521-x.
23. Kloiber, S., Ising, M., Reppermund, S., Horstmann, S., Dose, T., Majer, M., et al. Overweight and obesity affect treatment response in major depression. Biol. Psychiatry 62 (2007), 321–326, 10.1016/j.biopsych.2006.10.001.
24. Koo, J.W., Russo, S.J., Ferguson, D., Nestler, E.J., Duman, R.S., Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 2669–2674, 10.1073/pnas.0910658107.
25. Leverich, G.S., Altshuler, L.L., Frye, M.A., Suppes, T., Keck, P.E., McElroy, S.L., et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J. Clin. Psychiatry 64 (2003), 506–515.
26. Li, H., Hong, W., Zhang, C., Wu, Z., Wang, Z., Yuan, C., et al. IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J. Affect. Disord. 174 (2015), 361–366, 10.1016/j.jad.2014.12.033.
27. Lieberknecht, V., Antidepressant-like effect of pramipexole in an inflammatory model of depression. Behav. Brain Res. 320 (2017), 365–373, 10.1016/j.bbr.2016.11.007 Epub 2016 Nov 5.
28. Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 171 (2014), 160–168, 10.1176/appi.ajp.2013.13070984.
29. Maharshak, N., Arbel, Y., Gal-Oz, A., Rogowski, O., Shapira, I., Berliner, S., et al. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J. Dig. Dis. 9 (2008), 140–143.
30. Martin, D.J., Garske, J.P., Davis, M.K., Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J. Consult. Clin. Psychol. 68 (2000), 438–450.
31. McDade, T.W., Tallman, P.S., Madimenos, F.C., Liebert, M.A., Cepon, T.J., Sugiyama, L.S., et al. Analysis of variability of high sensitivity C-reactive protein in lowland Ecuador reveals no evidence of chronic low-grade inflammation. Am. J. Hum. Biol. 24 (2012), 675–681, 10.1002/ajhb.22296.
32. Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70 (2011), 663–671, 10.1016/j.biopsych.2011.04.013.
33. Munkholm, K., Weikop, P., Kessing, L.V., Vinberg, M., Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav. Immun. 43 (2015), 205–213, 10.1016/j.bbi.2014.09.021.
34. O'Connor, M.-F., Bower, J.E., Cho, H.J., Creswell, J.D., Dimitrov, S., Hamby, M.E., et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav. Immun. 23 (2009), 887–897, 10.1016/j.bbi.2009.04.005.
35. Ong, K.L., Allison, M.A., Cheung, B.M.Y., Wu, B.J., Barter, P.J., Rye, K.A., Trends in C-reactive protein levels in US adults from 1999 to 2010. Am. J. Epidemiol. 177 (2013), 1430–1442, 10.1093/aje/kws443.
36. Parker, G., McCraw, S., Hadzi-Pavlovic, D., Fletcher, K., Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J. Affect. Disord. 149 (2013), 46–55, 10.1016/j.jad.2012.10.002.
37. Pettai, K., Milani, L., Tammiste, A., Võsa, U., Kolde, R., Eller, T., et al. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. Eur. Neuropsychopharmacol. 26 (2016), 1475–1483, 10.1016/j.euroneuro.2016.06.007.
38. Powell, T.R., Schalkwyk, L.C., Heffernan, A.L., Breen, G., Lawrence, T., Price, T., et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur. Neuropsychopharmacol. 23 (2013), 1105–1114, 10.1016/j.euroneuro.2012.09.009.
39. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41, 10.1001/2013.jamapsychiatry.4.
40. Rapaport, M.H., Nierenberg, A.A., Schettler, P.J., Kinkead, B., Cardoos, A., Walker, R., et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol. Psychiatry 21 (2016), 71–79, 10.1038/mp.2015.22.
41. Ridker, P.M., Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003), 363–369.
42. Romeo, B., Choucha, W., Fossati, P., Rotge, J.Y., Clinical and biological predictors of ketamine response in treatment-resistant major depression: review. Encephale 43 (2017), 354–362.
43. Shelton, R.C., Manning, S.J., Barrentine, L.W., Tipa, E.V., Assessing effects of l-Methylfolate in depression management: results of a real-world patient experience trial. Prim Care Companion CNS Disord., 15, 2013, 10.4088/PCC.13m01520.
44. Sidor, M.M., Macqueen, G.M., Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J. Clin. Psychiatry 72 (2011), 156–167, 10.4088/JCP.09r05385gre.
45. Sienaert, P., Lambrichts, L., Dols, A., De Fruyt, J., Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipolar Disord. 15 (2013), 61–69, 10.1111/bdi.12026.
46. Tourjman, V., Kouassi, É., Koué M.-È., Rocchetti, M., Fortin-Fournier, S., Fusar-Poli, P., et al. Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 151 (2013), 43–47, 10.1016/j.schres.2013,10.011.
47. Turner, E.H., Matthews, A.M., Linardatos, E., Tell, R.A., Rosenthal, R., Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358 (2008), 252–260, 10.1056/NEJMsa065779.
48. Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 171 (2014), 1278–1286, 10.1176/appi.ajp.2014.14010094.
49. Walker, A.K., Budac, D.P., Bisulco, S., Lee, A.W., Smith, R.A., Beenders, B., et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 38 (2013), 1609–1616, 10.1038/npp.2013.71.
50. Yang, J.J., Wang, N., Yang, C., Shi, J.Y., Yu, H.Y., Hashimoto, K., Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol. Psychiatry 1:77 (2015), e19–e20.